You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
News and reporting on KRAS biomarkers.
The test is designed to detect cancer-driver gene variants associated with certain targeted solid tumor therapies, and is validated as a companion diagnostic.
The group plans to use the assay for translational studies on metastasis and drug resistance initially and to develop a clinical version later on.
In PNAS this week: genome-editing approach, analysis of KRAS-mutant cancers modeled in genetically engineered mice, and more.
The recent study highlights strengths and weaknesses of numerous platforms and may help end users choose the best assay for their circumstances.
UCSF will analyze Two Pore Guys' handheld nanopore device for its ability to detect a KRAS mutation from patient blood and urine samples.
The combination of the new test with Biocartis' existing KRAS assay offers customers a complete solution for testing metastatic colorectal cancers as reccomended by professional guidelines.
Newsweek reports that cancer researchers are cautiously optimistic that they will soon be able to target mutant Ras.
Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.
California researchers screened some 850 miRNAs to uncover one that inhibits growth in cancer cells with KRAS mutations, which are linked to poor survival.
Results from a recent study clarify some conflicting prior determinations, and provide a new rationale to further explore the FCGR2A biomarker in prospective trials.
A German shepherd called Nala has had her genome sequenced.
A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?
Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.
In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.